gastric cancer gastric cancer
Conditions
Interventions
1st cycle: 28 days per cycle
Weekly nab-paclitaxel (100mg/m2, Day1/Day8/Day15)
ramucirumab(8mg/kg, Day1/Day15)
(1) Patients have not received nab-paclitaxel due to toxicity on day 8 or 15 during 1st c
Not applicable
Sponsors
IZAWA Naoki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (2) age of 20 or more (3) presence of evaluable lesion (4) histopathologically confirmed gastric adenocarcinoma or gastroesophageal adenocarcinoma (5) unresectable or metastatic patients (6) refractory disease or unable to tolerate first line chemotherapy including fluoropyrimidines agents, or refractory disease after or during adjuvant chemotherapy including fluoropyrimidines agents (7) Patients must have the following adequate organ functions (8) Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
Exclusion criteria: (1)Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (2)age of 20 or more (3)presence of evaluable lesion (4)histopathologically confirmed gastric adenocarcinoma or gastroesophageal adenocarcinoma (5)unresectable or metastatic patients (6)refractory disease or unable to tolerate first line chemotherapy including fluoropyrimidines agents, or refractory disease after or during adjuvant chemotherapy including fluoropyrimidines agents (7)Patients must have the following adequate organ functions (8)Ability to understand and the willingness to sign a written informed consent document
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival(PFS) | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival(OS), response rate(RR), disease control rate(DCR), relative dose intensity, QOL | — |
Contacts
Public ContactNaoki Izawa
St.Marianna University School of Medicine Hospital
Outcome results
None listed